ArticleCell stem cell2023
TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal.
Open access · bronzeAbstract read
In one paragraph
Article in Cell stem cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed
15.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 100 citations in OpenAlex.
- Targeting Metabolic Pathways to Direct T-Cell Trafficking: Therapeutic Perspectives.Biomedicines · 2026Review
- TET2 aggravates podocyte mitotic catastrophe and renal injury in diabetic nephropathy via m5C-dependent downregulation of Wee1 and activation of CDK1-cyclinB1 signaling.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- DREAMS illuminates spatial DNA and RNA modification landscapes.Nature cell biology · 2026Article
- Rewiring of de novo serine synthesis supports tumorigenesis under deficiency of TET2.British journal of cancer · 2026Article
- Mechanistic Study of m5C Modification in Stem Cell Differentiation and Disease Regulation.Stem cell reviews and reports · 2026Review
- TET2 as a Context-Dependent Epigenetic Integrator in Clonal Hematopoiesis, Inflammation, Cancer, and Immunotherapy.Cell biochemistry and function · 2026Review
- Review
- Role of RNA 5‑methylcytosine modification in cancer: Insights from coding and non‑coding RNAs (Review).Molecular medicine reports · 2026Review
- Clonal hematopoiesis of indeterminate potential (CHIP)-a pivotal contributor of aging and related disorders.Annals of translational medicine · 2026Review
- Hepatitis B virus promotes hepatocellular carcinoma progression by disrupting NSUN2/YBX1-mediated mVirologica Sinica · 2026Article
- RNA modifications in cancer and their detection: a review.Japanese journal of clinical oncology · 2026Review
- Interplay of RNA mFASEB bioAdvances · 2026Article
- SRC as a Prognostic and Immunomodulatory Biomarker in Acute Myeloid Leukemia: A Multi-Omics Study.International journal of molecular sciences · 2026Article
- TET2 in epigenetic control of immune cells: Implications for inflammatory responses and age-related pathologies.The Journal of biological chemistry · 2026Review
- Tetraspanin 13 Enhances Immune Evasion in Breast Cancer by Promoting MHC-I Degradation.Cancer research · 2026Article
- Hematopoietic stem cell aging promotesResearch square · 2026Article
- Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications.Cancer cell · 2026Review
- RNA modification systems as therapeutic targets.Nature reviews. Drug discovery · 2026Review
- The role of epigenetic modifications in cancer-associated fibroblasts.Frontiers in medicine · 2026Review
- RNA modifications in cancer stem cells: molecular mechanisms and targeted therapeutic strategies.Frontiers in cell and developmental biology · 2026Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 9 institutions in 2 countries.
Yangchan LiDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China.
Meilin XueDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Xiaolan DengDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Lei DongDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Le Xuan Truong NguyenGehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA; Department of Hematological Malignancies Translational Science, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Lili RenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Department of Pathology, Harbin Medical University, Harbin 150081, China.
Li HanDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110001, Liaoning, China.
Chenying LiDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 31003, Zhejiang, China.
Jianhuang XueDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Zhicong ZhaoDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Wei LiDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Ying QingDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Chao ShenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Brandon TanDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Zhenhua ChenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Keith LeungDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Kitty WangDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Srividya SwaminathanDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Department of Pediatrics, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Ling LiGehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA; Department of Hematological Malignancies Translational Science, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Mark WunderlichDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
James C MulloyDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Xiaobo LiDepartment of Pathology, Harbin Medical University, Harbin 150081, China.
Hao ChenDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Bin ZhangGehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA; Department of Hematological Malignancies Translational Science, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
David HorneCity of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA; Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Steven T RosenGehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA; City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA; Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA 91010, USA.
Guido MarcucciGehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA; Department of Hematological Malignancies Translational Science, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Mingjiang XuDepartment of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Zejuan LiDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA.
Minjie WeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110001, Liaoning, China.
Jingyan TianState Key Laboratory of Medical Genomics, Clinical Trial Center, Shanghai Institute of Endocrine and Metabolic Diseases, Department of Endocrinology and Metabolism, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: tianjypaper@163.com.
Baiyong ShenDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: shenby@shsmu.edu.cn.
Rui SuDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Electronic address: rsu@coh.org.
Jianjun ChenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA; City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Electronic address: jianchen@coh.org.
City of Hope · USShanghai Jiao Tong University · CNCincinnati Children's Hospital Medical Center · USHarbin Medical University · CNChina Medical University · CNCity Of Hope National Medical Center · USMethodist Hospital · USSun Yat-sen University · CNThe University of Texas Health Science Center at San Antonio · US
Funding
The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemiaR01CA271497 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Jianjun Chen · 2022 to 2026
$2.8MTargeting FTO to treat acute myeloid leukemiaR01CA243386 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2024
$2.8MTET2-mediated epitranscriptomic regulation in leukemia microenvironmentR01CA280389 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Jianjun Chen · 2023 to 2026
$2.7MThe role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AMLR01CA236399 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2019 to 2023
$2.3MTargeting TET1 signaling to treat acute myeloid leukemiaR01CA211614 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.3MThe function and underlying mechanism of TET1 in myelodysplastic syndromesR01DK124116 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2023
$2.2MThe role and mechanism of FTO in leukemogenesis and drug responseR01CA214965 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.1MDNA Damage Response and Oncogenic SignalingT32CA186895 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BINGHUI SHEN, Jeremy Michael Stark · 2016 to 2026
$2.1MPotential therapeutic implications of targeting miR-150 in acute myeloid leukemiaR01CA182528 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7MThe role and functional mechanism of TET1 in MLL-rearranged leukemiaR01CA178454 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7MThe role and functional mechanism of a miRNA cluster, mir-17-92 in leukemogenesisR01CA127277 · NCI · UNIVERSITY OF CHICAGO · PI CHEN, JIANJUN · 2008 to 2012
$1.4MNCI NIH HHS R01 CA127277NCI NIH HHS R01 CA178454NCI NIH HHS R01 CA182528NCI NIH HHS R01 CA211614NCI NIH HHS R01 CA214965NCI NIH HHS R01 CA236399NCI NIH HHS R01 CA243386NCI NIH HHS R01 CA271497NCI NIH HHS R01 CA280389NCI NIH HHS T32 CA186895NIDDK NIH HHS R01 DK124116
Abstract
TET2 is recurrently mutated in acute myeloid leukemia (AML) and its deficiency promotes leukemogenesis (driven by aggressive oncogenic mutations) and enhances leukemia stem cell (LSC) self-renewal. However, the underlying cellular/molecular mechanisms have yet to be fully understood. Here, we show that Tet2 deficiency significantly facilitates leukemogenesis in various AML models (mediated by aggressive or less aggressive mutations) through promoting homing of LSCs into bone marrow (BM) niche to increase their self-renewal/proliferation. TET2 deficiency in AML blast cells increases expression of Tetraspanin 13 (TSPAN13) and thereby activates the CXCR4/CXCL12 signaling, leading to increased homing/migration of LSCs into BM niche. Mechanistically, TET2 deficiency results in the accumulation of methyl-5-cytosine (m
Indexed as
DioxygenasesLeukemia, Myeloid, AcuteBone MarrowCarcinogenesisDemethylationDNA-Binding ProteinsHumansNeoplastic Stem CellsRNA, MessengerStem CellsTetraspaninsDioxygenasesDNA-Binding ProteinsRNA, MessengerTET2 protein, humanTetraspaninsTSPAN13 protein, humanbone marrow microenvironmentCXCR4homingleukemia stem cellmigrationRNA 5-methylcytosine methylationself-renewalTET2TSPAN13YBX1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.